Ultragenyx Pharmaceutical (RARE) Cash from Operations (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Cash from Operations of 197000000.0 for Q1 2026, down 18.67% year-over-year from 242237037.04 in Q1 2025, and down 97.34% quarter-over-quarter from 99829000.0 in Q4 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) Cash from Operations (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Cash from Operations for 14 consecutive years, with 197000000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 18.67% year-over-year to 197000000.0; the TTM figure through Mar 2026 stood at 497000000.0 (down 27.67% YoY), while the FY2025 annual figure was 466000000.0, down 12.56% from the prior year.
- Cash from Operations retreated to 197000000.0 in Q1 2026 per RARE's latest filing, from 99829000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 66995000.0 in Q3 2024 and bottomed at 197000000.0 in Q1 2026.
- Historically, Cash from Operations has averaged 113674411.76 across 5 years, with a median of 99829000.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Operations plunged 66.24% — and 2024, when it surged 43.16%.
- Ultragenyx Pharmaceutical's Cash from Operations stood at 90342000.0 in 2022, then advanced by 6.91% to 84098000.0 in 2023, then gained by 5.69% to 79315000.0 in 2024, then retreated by 25.86% to 99829000.0 in 2025, then tumbled by 97.34% to 197000000.0 in 2026.
- Business Quant data shows RARE's Cash from Operations at 197000000.0 in Q1 2026, 99829000.0 in Q4 2025, and 91423000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | -97.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -97.00 Mn |
| Mar 31, 2026 | -197.00 Mn |
| Dec 31, 2025 | -99.83 Mn |
| Sep 30, 2025 | -91.17 Mn |
| Jun 30, 2025 | -109.00 Mn |
| Mar 31, 2025 | -166.00 Mn |
| Dec 31, 2024 | -79.32 Mn |
| Sep 30, 2024 | -67.00 Mn |
| Jun 30, 2024 | -76.96 Mn |
| Mar 31, 2024 | -190.73 Mn |
| Dec 31, 2023 | -84.10 Mn |
| Sep 30, 2023 | -117.87 Mn |
| Jun 30, 2023 | -116.16 Mn |
| Mar 31, 2023 | -156.87 Mn |
| Dec 31, 2022 | -90.34 Mn |
| Sep 30, 2022 | -95.35 Mn |
| Jun 30, 2022 | -77.26 Mn |
| Mar 31, 2022 | -117.52 Mn |
| Dec 31, 2021 | -54.34 Mn |
| Sep 30, 2021 | -59.65 Mn |